Results 131 to 140 of about 444,347 (295)

The Effect of Chronic Consumption of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists on Blood Pressure and Inotrope Consumption After Separation from Cardiopulmonary Bypass. [PDF]

Anesth Pain Med, 2018
Hassani E, Mahoori A, Karami N, Hassani A, Hassani L.   +4 more
europepmc   +1 more source

A Delphi consensus project to capture experts' opinion on hyperkalaemia management across the cardiorenal spectrum

ESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.
Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou, Maria Marketou, Maria Aktsiali, Ioannis Griveas   +3 more
wiley   +1 more source

Structural and Computational Insights into the Angiotensin II Type 1 Receptor: Advances in Antagonist Design and Implications for Hypertension Therapy (2020-2024). [PDF]

Biomolecules
Chatzipieris FP, Petsas E, Lambrinidis G, Matsoukas JM, Mavromoustakos T.   +4 more
europepmc   +1 more source

Effects of AT1 and AT2 angiotensin receptor antagonists in angiotensin II-infused rats.

HYPERTENSION, 1998
Jin S. Li, R. Touyz, E. Schiffrin
semanticscholar   +1 more source

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran, Vinay Randhawa, Usman A. Tahir, Matthew Robertson, Anam A. Waheed, Anna Perillo, Leanne Barrett, Ron Blankstein, Mark W. Feinberg, Marcelo F. Di Carli, Neal K. Lakdawala   +10 more
wiley   +1 more source

Management of chronic kidney disease in a 65-year-old man with diabetes. [PDF]

CMAJ
Dubrofsky L, Cherney DZI, Odutayo A.
europepmc   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Molecular Mechanisms and Clinical Evidence Supporting the Four Pillars of Therapy in Diabetic Kidney Disease: Emerging Therapeutic Perspectives. [PDF]

Int J Mol Sci
Yanai H, Adachi H, Hakoshima M, Katsuyama H.   +3 more
europepmc   +1 more source

Long-term mortality and treatment outcomes in pacemaker-associated heart failure: insights from a nationwide propensity-matched study. [PDF]

Eur Heart J Open
Park YJ, Lee S, Hong S, Kim K, Kim J, Kim JY, Park KM, On YK, Park SJ.   +8 more
europepmc   +1 more source

Angiotensin II Receptor Antagonist [PDF]

, 2020
openaire   +1 more source